ERBB2 and neoplasm: In the multivariate model which includes hormone receptor status, tumor size (T) and presence of lymph‐node metastases (N), HER2 levels by SRM‐MS independently predicted DFS in the adjuvant setting (HR = 0.25; 95% CI: 0.06 to 0.96; p = 0.044) (Table 3).